Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Nuvalent, Inc. Market Cap
From what 2 stock analysts predict, the share price for Nuvalent, Inc. (NUVL) might decrease by 13.58% in the next year. This is based on a 12-month average estimation for NUVL. Price targets go from $69.00 to $80.00. The majority of stock analysts believe NUVL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedNUVL 1 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Nuvalent, Inc. to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on NUVL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| christopher raymond Piper Sandler | Buy | $80.0 | rated | Jan 19, 2024 |
| christopher liu Leerink Partners | Hold | $69.0 | maintained | Jan 8, 2024 |
| etzer darout BMO Capital | Buy | $79.0 | reiterated | Nov 14, 2023 |
| marc frahm TD Cowen | Buy | None | maintained | Nov 14, 2023 |
| bradley canino Stifel Nicolaus | Buy | $100.0 | maintained | Oct 17, 2023 |
| anupam rama J.P. Morgan | Buy | $68.0 | maintained | Oct 4, 2023 |
| charles zhu Guggenheim | Buy | $56.0 | initiatedcoverage | Jul 24, 2023 |
| david nierengarten Wedbush | Buy | $39.0 | initiatedcoverage | Jan 17, 2023 |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2021
Staff Count
89
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. James R. Porter Ph.D.
Market Cap
$5.40B
In 2023, NUVL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that NUVL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
CNXC-USD
$81.94
BECN-USD
$85.89
PEGA-USD
$64.88
BPMC-USD
$86
BOKF-USD
$83.58
LANC-USD
$193.94
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
